Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefmetazole is a semisynthetic cephamycin antibiotic, usually grouped with the second-generation cephalosporins. It exhibits a broad spectrum of activity against both gram-positive and gram-negative bacteria, including anaerobes such as Bacteroides fragilis. Cefmetazole is particularly effective against beta-lactamase-producing organisms that are resistant to first-generation cephalosporins or penicillins. Its mechanism of action involves inhibition of bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. The drug is administered parenterally (intravenous or intramuscular) and is used for treating respiratory tract, skin and soft tissue, urinary tract, gynecologic infections, as well as for perioperative prophylaxis in certain surgical procedures[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefmetazole.